Biogen, Ionis End ALS Program; Ionis Will Advance Angelman Asset Alone

Long-Time Partners Decide Fate Of Two Drugs

Development has ended for BIIB105 in ALS after it failed to clear a crucial biomarker and show clinical benefit. Also, Biogen opted not to advance ION582 for Angelman syndrome, so Ionis will go it alone.

Illustration of abstract neuron on a blue background
Ionis will bolster its in-house neurology portfolio with wholly-owned ION582 • Source: Shutterstock

Long-time collaborators Biogen, Inc. and Ionis Pharmaceuticals, Inc. announced updates for two programs in mid-stage clinical development on 16 May, reporting that they will end development of BIIB105 after the drug failed in a Phase I/II clinical trial in amyotrophic lateral sclerosis (ALS). Ionis also revealed updated results from a Phase I/IIa trial of ION582 (BIIB121) in Angelman syndrome and said it will take the drug into Phase III on its own after Biogen opted out of the program.

Key Takeaways
  • Biogen and Ionis will discontinue development of BIIB105 for ALS after the drug failed to provide clinical benefit in a Phase I/II study.

Both companies traded lower on the updates, with Biogen closing down 2.2% at $230.04 per share and Ionis ending the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: Organon To Pull Plug On OG-6219 Program After Phase II Endometriosis Trial Failure

 

Once hailed as a potential game changer, OG-6219 gets the axe after failing in a Phase II endometriosis-related pain trial.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By 

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

More from R&D

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By 

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.